Literature DB >> 21360537

Prospective comparison of peritumoral and subareolar injection of blue dye alone, for identification of sentinel lymph nodes in patients with early stage breast cancer.

Ioannis G Kaklamanos1, Konstantinos Birbas, Konstantinos Syrigos, Vasilios G Bonatsos, Gerasimos Bonatsos.   

Abstract

BACKGROUND AND OBJECTIVES: Various techniques are used for the identification of the sentinel node (SLN). We prospectively compare the efficacy of SLN biopsy and the number of SLNs identified, by injecting methylene blue (MB) alone in the subareolar area (SA) or peritumorally (PT) in patients with early stage breast cancer.
METHODS: Patients were randomized in two groups (SA or PT injection). A linear regression model was used to estimate the effect of various parameters on the identification rate and on the number of SLNs retrieved.
RESULTS: At least one SLN was identified in 61 of 66 (92.4%) procedures in the SA group and in 57 of 60 (95%) procedures in the PT group (P = 0.55). The mean number of SLNs removed with the SA injection method was 1.64 ± 0.6 nodes compared with 2.23 ± 0.7 nodes identified with the PT injection (range: 1-4, P < 0.001). The injection site was the only factor affecting the number of SLNs retrieved.
CONCLUSION: The use of MB alone is an efficient method for identification of the SLN. The PT injection route yields a higher number of SLNs than the SA route, comparable with the number of SLNs retrieved, when combined tracing agents and multiple injection sites are used.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360537     DOI: 10.1002/jso.21897

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years.

Authors:  Yoshinari Ogawa; Katsumi Ikeda; Kana Ogisawa; Shinya Tokunaga; Hiroko Fukushima; Takeshi Inoue; Yoshihiro Mori; Akiko Tachimori; Toru Inoue; Yukio Nishiguchi
Journal:  Surg Today       Date:  2013-09-26       Impact factor: 2.549

2.  Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: A systematic review and meta-analysis.

Authors:  Jiyu Li; Xiao Chen; Ming Qi; Yanshuang Li
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

3.  Methylene Blue Near-Infrared Fluorescence Imaging in Breast Cancer Sentinel Node Biopsy.

Authors:  Oliver Budner; Tomasz Cwalinski; Jarosław Skokowski; Luigi Marano; Luca Resca; Natalia Cwalina; Leszek Kalinowski; Richelle Hoveling; Franco Roviello; Karol Polom
Journal:  Cancers (Basel)       Date:  2022-04-03       Impact factor: 6.639

4.  Diagnostic performance and survival outcome following sentinel lymph node biopsy in breast cancer patients from a tertiary cancer centre in India.

Authors:  Sanjit Kumar Agrawal; Himanshu Sharma; Noopur Priya; Anoop P Saji; Hamyung Denchu Phom; Abhishek Sharma; Indu Arun; Jayanta Das; Aditi Chandra; Rosina Ahmed
Journal:  Ecancermedicalscience       Date:  2022-05-26

5.  A novel finding of sentinel lymphatic channels in early stage breast cancer patients: which may influence detection rate and false-negative rate of sentinel lymph node biopsy.

Authors:  Minghai Wang; Wenbin Zhou; Yingchun Zhao; Tiansong Xia; Xiaoming Zha; Qiang Ding; Xiaoan Liu; Yi Zhao; Lijun Ling; Lin Chen; Shui Wang
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

6.  Comparison between sentinel lymph node hybrid scintigraphy and blue dye technique in breast cancer patients: An institutional experience.

Authors:  Maimoona Siddique; Aamna Hassan; Muhammad Khalid Nawaz; Humayun Bashir; Muhammad Zulqarnain Chaudhry
Journal:  World J Nucl Med       Date:  2020-01-29

7.  Outcomes of Sentinel Lymph Node Biopsy Using Blue Dye Method for Early Breast Cancer - A Single-Institution Experience in the Philippines.

Authors:  Ralph Victor Yap; Frances Marion De La Serna
Journal:  Breast Cancer (Dove Med Press)       Date:  2020-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.